Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma.
Explore this paper's citation graph
Summary
PCLI and beta 2M measured at diagnosis are independent prognostic factors and must be considered when interpreting the results of clinical trials and should be helpful in counseling patients and in designing new trials.
- Type
- article
- Published
- 1993-06-15
- Cited by
- 264
- References
- 22
- Access
- Open access
- OpenAlex
- https://openalex.org/W1781784766
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:24774304
Keywords
Beta-2 microglobulin, Medicine, Multiple myeloma, Internal medicine, BETA (programming language)
References
- Ploidy and proliferative characteristics in monoclonal gammopathies.
- Heterogeneous modulation of acute-phase-reactant mRNA levels by interleukin-1 beta and interleukin-6 in the human hepatoma cell line PLC/PRF/5.
- Value of beta 2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma.
- C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system.
- Multiple myeloma: significance of plasmablastic subtype in morphological classification.
- Therapeutic implications of myeloma staging *
- Serum thymidine kinase as a marker of disease activity in patients with multiple myeloma.
- Immunofluorescence labeling indices in myeloma and related monoclonal gammopathies.
- A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival
- Prognostic factors and classification in multiple myeloma.
- Multiple myeloma. An update on diagnosis and management.
- Evaluation of serum deoxythymidine kinase as a marker in multiple myeloma
- A new prognostic system for multiple myeloma based on easily available parameters
- Beta2 microglobulin in multiple myeloma
- Staging systems for multiple myeloma: a comparison
- Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia.
- Prognostic variables and clinical staging in multiple myeloma.
- Prognostic factors in multiple myeloma: definition of risk groups in 410 previously untreated patients: a Grupo Argentino de Tratamiento de la Leucemia Aguda study.
- Serum Thymidine Kinase and Beta-2 Microglobulin in Monoclonal Gammopathies
- Multiple myeloma: biological and clinical significance of bone marrow plasma cell labelling index.
Cited by
- Toward Personalized Medicine: The potential role of RNA interference in Plasma Cell Dyscrasia
- Risk stratification of patients with newly diagnosed multiple myeloma: optimizing treatment based on pretreatment characteristics.
- Risk Stratification in the Era of Novel Therapies
- Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma
- Prognosis in multiple myeloma.
- Plasmablastic morphology--an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group.
- The role of the bone marrow microenvironment in multiple myeloma.
- Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Finnish Leukemia Group.
- The plasma cell dyscrasias.
- Risk stratification in multiple myeloma, part 1: characterization of high-risk disease.
- Molecular pathogenesis of multiple myeloma: chromosomal aberrations, changes in gene expression, cytokine networks, and the bone marrow microenvironment.
- Prognostic value of numerical chromosome aberrations in multiple myeloma: A FISH analysis of 15 different chromosomes.
- Effects of interferon alpha on myeloma cells: mechanisms of differential responsiveness.
- Plasma cell labeling index.
- Hepatocyte growth factor, c-Met and syndecan-1 in multiple myeloma
- 多発性骨髄腫における予後因子としてのBUN, Bence Jones蛋白，および染色体異常
- Diagnostic and Therapeutic Advances in Hematologic Malignancies
- Serum syndecan-1: a new independent prognostic marker in multiple myeloma.
- High expression of endoplasmic reticulum chaperone grp94 is a novel molecular hallmark of malignant plasma cells in multiple myeloma
- A rare case of non‐secretory multiple myeloma without bone marrow involvement
Related papers
- [Serum beta-2-microglobulin in multiple myeloma. Practical value].
- Pretreatment serum beta 2-microglobulin in multiple myeloma.
- Multiple myeloma: beta-2-microglobulin is not a useful follow-up parameter.
- Prognostic significance of pretreatment serum β2-microglobulin levels in multiple myeloma
- Alpha interferon raises serum beta‐2‐microglobulin in patients with multiple myeloma
- Clinical analysis of multiple myeloma:a report of 102 cases
- Serum beta 2 microglobulin in multiple myeloma. A critical review.
- Analyzing the Prognostic Factors of Multiple Myeloma